Biophotonic blood test to spot pancreatic cancer risk in at‑risk adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

LASERBLOOD uses biophotonic signals from a blood sample to predict progression to pancreatic ductal adenocarcinoma in adults with risk factors such as diabetes, obesity, or IPMN. The study involves diagnostic procedures intended to identify PDAC risk and to monitor treatment effectiveness in participants. Eligible participants are adults with PDAC or IPMN, without prior cancer, and with stable organ function, while excluding those with severe comorbidities or on therapies that may confound results. The trial is conducted at a single center in Rome, Italy, under the Fondazione Policlinico Universitario Campus Bio-Medico leadership.

Why it matters

Who can join: the full rules

\*\*Inclusion criteria for patients with PDAC and IPMN:\*\*

* No history of prior neoplastic diseases;
* Adequate renal and hepatic function;
* No hematologic disorders;
* Age ≥ 18 years;
* No active infections;
* Written informed consent.

\*\*Exclusion criteria:\*\*

* Severe pre-existing medical conditions, such as serious illnesses or other medical conditions that could negatively affect study outcomes or pose a high risk to the patient's health;
* Ongoing therapies that could interfere with the study or alter the results.

Where it's running

• Fondazione Policlinico Universitario Campus Bio-Medico
  Rome, Italy, Italy Recruiting

Study contacts

• Study coordinator: Damiano Caputo, MD
• Email: d.caputo@policlinicocampus.it
• Phone: +3906225418012

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Preventing complications after high-risk Whipple (pancreatoduodenectomy) with hydrocortisone, octreotide, and a teres ligament patch

  This tests whether giving hydrocortisone and octreotide around surgery plus placing a teres ligament patch can lower major complications after Whipple surgery in patients with a small pancreatic duct.

  Recruiting Phase 4 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam · NCT07262957

• AI-assisted 4D PET imaging to detect early pancreatic cancer lesions

  This study tests whether AI-assisted 4D long-axial PET imaging with FDG and FAPI can help detect early PDAC lesions in patients with suspected pancreatic tumors.

  Recruiting Ruijin Hospital · Shanghai · NCT07925125

• New virtual care pathway for older adults with chronic diseases

  A teleconsultation-based care pathway for adults 60+ with hypertension, diabetes, or dyslipidemia to see if it’s feasible and cost-saving in Malaysian primary care compared with usual clinic visits.

  Recruiting National University of Malaysia · Kuala Lumpur · NCT07843238

• Benefits of Retained Insulin for Good Health in Diabetes

  This study tests whether preserving or restoring a person’s own insulin production can improve quality of life and blood sugar control for people who need insulin to manage diabetes.

  Recruiting at 4 sites Royal Devon and Exeter NHS Foundation Trust · Truro, Cornwall and 3 other locations · NCT07828626

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Improving Care for underserved older Black patients with cardiovascular and other chronic conditions

  This study tests a culturally tailored approach to patient-centered care for older African American patients with cardiovascular disease and other conditions who receive care at a community hospital.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT07748858

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.